For the past several months, DrugNews has reported on growing concerns that power morcellator devices used in many hysterectomies could spread uterine cancer.
Since April, the FDA has launched an investigation and advised doctors of potential risks. The largest manufacturer of the devices has also stopped selling them for the time being.
Prior to losing its patent protection on January 1, 2014, the antidepressant drug Cymbalta was the top-selling drug for pharmaceutical giant Eli Lilly. Now, the company is facing a growing number of lawsuits claiming the medication caused debilitating withdrawal side effects.
Last month, lawyers representing former Cymbalta users around the country asked a federal judicial panel to move all cases to one central court for more efficient handling. If granted, the move would create a Cymbalta multidistrict litigation (MDL) court where victims can share legal resources and pursue their individual suits.
So far, nearly 1,000 women have filed lawsuits over the popular IUD contraceptive Mirena after suffering serious uterus perforations that required surgery.
Now, a growing number of lawsuits over a different issue indicate the birth control insert from Bayer may have other dangers as well.
Last month, German drug manufacturer Bayer released their latest financial reports showing sales of the once-leading birth control pill Yaz has slowed by more than 10% in the past year.
Hidden deep in those records was additional information showing the company has spent nearly $2 billion on settlements for those who have been hospitalized for blood clots issues like stroke, deep vein thrombosis or pulmonary embolism.
Last week, DrugNews reported on a newly-discovered and potentially dangerous side effect of the popular Mirena IUD contraceptive: intracranial hypertension that can cause neurological problems, blindness or hearing loss.
So far, at least ten women have filed lawsuits in federal courts alleging the device caused them to suffer headaches, hearing loss or permanent vision problems.
After two years and nearly $2 billion in settlements to victims of Yaz blood clots, German drug maker Bayer is finally seeing a drop in the number of lawsuits filed against their popular birth control drugs Yaz and Yasmin.
The Judicial Panel on Multidistrict Litigation, which oversees federal mass tort litigation against hundreds of allegedly dangerous products around the country, reported today that the number of pending Yaz lawsuits had dropped from 9,426 on April 15 to 8,919 as of June 16.
Last month, the FDA and other women’s health experts warned of the dangers of undergoing laparoscopic hysterectomies and myomectomies due to the risk that morcellation surgical devices may spread undetected uterin cancer.
The news caused several top hospitals to stop performing the procedures, and J&J, who sells 75% of all morcellators in the United States, to halt sales.
The anticoagulant drug Xarelto has emerged as one of the most popular drugs on the market for preventing blood clots in patients with atrial fibrillation or who recently underwent surgery.
Xarelto, along with competitors Pradaxa and Eliquis, has surpassed stalwart drug warfarin as the go-to option since it doesn’t require regular blood testing or changes to diet. However these newer blood thinners may have more serious risks of internal bleeding.
Women who’ve taken the birth control pills Yaz, Yasmin, Ocella or Gianvi were alerted to a new safety warning last month when the U.K.’s Medicines and Healthcare Products Regulatory Agency advised the drugs could cause blood clots.
This follows years of warnings about Yaz blood clots from experts around the world including the FDA, Health Canada, European Medicines Agency and New England Journal of Medicine.
Healthcare experts in the United Kingdom last month became the latest to warn that a popular form of birth control might present dangers to women.
The recent warning was targeted at combination oral contraceptives like Yasmin and Yaz that use the progestin hormone drospirenone, saying they could increase blood clot risks.
In November, medical device giant Johnson & Johnson agreed to begin settling thousands of lawsuits from patients who were injured by the defective DePuy ASR metal hip implants, which were recalled in 2010.
News reports stated that the settlement could be worth a potential $4 billion after all was said and done. However, many of those affected don’t know the details, whether they qualify or what steps they need to take to receive compensation.